Therapeutical Effects of Pleural Injecting Recombinant Human Endostain to 
Malignant Pleural Effusion Nude Mice Model

Abstract

Background and objective The prognosis of malignant pleural effusion (MPE) was poor, injecting anti-angiogenesis agents in pleural cavity might be to reducing the volume of pleural effusion. The aim of this study is to investigate the therapeutical effect of pleural injection of recombinant human endostain, cisplatin and recombinant human endostain combined with cisplatin to MPE nude mice. Methods MPE model was built by intrpleural injection of Lewis lung cancer cells (LCC) into BALB/c nude mice. Intrpleural injection of recombinant human endostain (E), cisplatin (P) and recombinant human endostain combined with cisplatin (EP) was performed, MPE volume was measured, immunohistochemistry of CD31 was carried out to calculate micro vessel density (MVD), angiogenesis and apoptosis gene expression was detected. Results MPE volume was reduced by intrapleiral injection of recombinant human endostain and recombinant human endostain combined with cisplatin, MPE volume was positive correlated with MVD. Vescular epidermal growth factor-α (VEGF-α) expression reduced simultaneously with expression of hypoxia induced factor-1 (HIF1-α) elevated at the same time. Conclusion MPE model could be made by intrapleural injection of LLC. Intrapleural injection of recombinant human endostain could reduce MPE volume of nude mice. The potential molecular mechanism of the therapeutical effects of intapleural injection of recombiant endostatin might be related to the downregulation of VEGF-α expression and neovascularization.

Keywords

• Lung neoplasms
• Pleural effusion
• Recombinant human endostain